Abstract
Background: Randomized dupilumab clinical trials have demonstrated rapid and sustained long-term efficacy with an acceptable safety profile in patients with moderate-to-severe atopic dermatitis (AD); however, real-world data are limited. We report early trends of the initial 6 months of real-world dupilumab treatment from an interim analysis of patients in the PROSE registry.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
